Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity. BPD is a chronic respiratory disease related to lung-injury during the primary course of critical lung disease such as respiratory distress syndrome or when abnormal development of the preterm lung occurs. Abnormal lung development not only results from primary lung injury in the first days after birth, but also secondary injury through abnormal repair resulting in arrested and abnormal alveolarization, fibrosis and pulmonary vascular dysgenesis. Chorioamnionitis is a risk factor that plays an important role in the development of BPD. Ureaplasma subspecies (spp.) are the most common isolated organisms from chorioamniotic tissue after premature births. Therefore Ureaplasma spp. appear to play an important role in the development of BPD, and treatment or prophylactic treatment of these infections or coloni zation may reduce the incidence, morbidity and mortality of BPD. Ureaplasma spp. infections are challenging not only to treat, but also to diagnosis in a timely manner. This review summarizes the current state of treatment and new developments in the treatment of Ureaplasma exposure in premature infants.
INTRODUCTION
Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity 1) .
BPD is a chronic respiratory disease related to lung-injury during the primary course of critical lung disease such as respiratory distress syndrome or abnormal lung development in utero and postnatally. Abnormal lung development occurs not only through primary lung injury in the first days after birth, but also secondary lung injury through abnormal repair resulting in arrested and abnormal alveolarization, fibrosis and pulmonary vascular dysgenesis. The definition and classification of BPD have changed since it was first described in 1967 by Northway et al. 2) . Currently, the most frequently used definition of BPD is as persistent oxy gen dependency for up to 28 days of life. The severity of BPD is more accurately predicted by the oxygen dependence at 36 weeks' postmenstrual age in infants born younger than 32 weeks gestational age and at 56 days of age in infants with older gesta tional age.
BPD is a multifactorial disease. These multifactorial influences occur postnatally as mechanical ventilation, oxygen toxicity, and sepsis. In addition to these postnatal factors, prenatal exposures may prime the lung for BPD development, such as through chorioamnionitis and maternal glucocorticosteroid administration 3) . These different factors may affect the develop ment and severity of BPD in individual premature infants 1, 4) . Despite ongoing research on the development and treat ment of BPD, treatment options are limited. Therefore BPD remains a major health issue in preterm infants, as BPD affects not only health care costs, but more importantly, the subsequent growth and neurodevelopment of the affected preterm baby 5) .
There is growing evidence that prenatal factors influence the development of BPD, and prophylactic therapy to prevent BPD may play a key role in the future. However, limited research data are available.
This review summarizes the current state of treatment and new developments in the treatment of Ureaplasma exposure in premature infants.
UREAPLASMA AND BPD -EPIDEMIOLOGY
Chorioamnionitis is one risk factor that plays an important role in the development of BPD 6) . Ureaplasma spp. are the most common isolated organisms from chorioamniotic tissue after premature births 7) . Intra-uterine colonization and infections with Ureaplasma spp. led to altered lung development, prolonged inflammatory response and increased fibrotic reac tion in animal models [7] [8] [9] [10] . In a previous meta-analysis, Wang and Schelonka, suggested that there is an association between postnatal Ureaplasma infection and BPD development 9, 11) .
Therefore, Ureaplasma spp. appear to play an important role in the development of BPD, and thus treatment or prophylactic treatment of these infections or colonization may reduce the incidence, morbidity and mortality of BPD.
Ureaplasma has been detected not only in the placentas and amniotic fluid, but also in the cord blood, cerebrospinal fluid, respiratory secretions, gastric aspirates, brain and lung tissue of preterm infants, and therefore is associated with adverse pregnancy and neonatal morbidity of prematurity 9, 12) . Its clinical influence and relevance on the development of BPD and respiratory tract colonization has been demonstrated in four meta analyses in the past 20 years 7, 9, 11, 13) . Further studies reported that the incidence of colonization ranged from rates 20
to 45% in very low birth weight infants 14) . A high incidence has been reported, and it has been shown that the risk of colonization increases with decreasing gestational age. Sixty-five percent of infants less than 26 weeks' gestation were culture-or PCR-positive one or more times during the first month of life compared to 31% of infants 26 or more weeks gestational age 12, 15) .
UREAPLASMA SPP. -CHARACTERISTICS
Among Ureaplasma spp., U. parvum and U. urealyticum are the most commonly isolated pathogens from infected placentas and amniotic fluid. U. parvum is isolated in 63% of respiratory cultures of neonatal respiratory samples at all ages. U. parvum serovars 3 and 6 account for 96% of these isolates. For U. urealy ticum is serovar 11 the most common type isolated 12) . There is no difference in morbidity between U. parvum (serovar 1, 3, 6, and 14) and U. urealyticum (serovar 2, 4, 5, 7-13) 10, 12) . There is no difference in the prevalence of either species between infants with or without BPD 13, 16) . Thus, Ureaplasma spp. act as pathogens, but there is no difference between species con cerning the clinical outcome ( Figure 1 ).
UREAPLASMA AND PATHOPHYSIOLOGY
How do these pathogens function in the pathogenesis of BPD?
Ureaplasma spp. adhere to the human mucosal surfaces of the genitourinary tract in adults and respiratory tract in newborns.
Ureaplasma spp. may contribute to cell damage of pneumocytes by virulent factors. First, Ureaplasma spp. activate different Tolllike-receptors as observed in the results of in vitro studies 17, 18) .
Ureaplasma spp. induce the production of tumor necrosis factoralpha, interleukin (IL)-6 and apoptosis of human type 2 lung epithelial cells and lung macrophages. Second, Ureaplasma spp. are known to induce antibody production in both humans and animals 19) . In vitro models, it also has been shown that sur- . This indicates that early treatment of maternal Ureaplasma infections in utero should be considered or that pro phylactic treatment may be important for preventing the development of BPD. Despite these finding regarding the pathophysiologic behavior of Ureaplasma, the exact influence on the development of BPD remains unknown.
UREAPLASMA AND DIAGNOSIS
In premature infants, analysis of Ureaplasma spp. in the tracheal aspirate can be performed via culture identification assay and/or polymerase chain reaction (PCR) 12, 21) . Culture re- . However, no neonatal clinical trials have been performed using this method.
Recently, a study analyzed gastric fluid versus amniotic fluid of preterm infants for the identification of intra uterine infec tions 22) .
Amniotic fluid analysis showed however better results. Gastric fluid analysis shows 100% specificity in the identification, but if am niotic fluid tested positive for Ureaplasma and gastric fluid was negative, there was still a higher rate of neonatal mortality. azithromycin therapy 7) . Pharmacokinetic studies by Hassan et al. 27, 28) showed that azithromycin at a dose of 20 mg/kg/day for 3 days was safe and resulted in better clearance of Ureaplasma spp. compared to results of Ballard in 2011 26) . 12) . Solithromycin is acid stable, and well tolerated, and shows superior tissue accumulation and effi cient maternalto-fetal transfer. Thus far, all Ureaplasma spp. tested were sensitive to solithromycin, indicating its promise as an agent for treating intra uterine infections. However, it has not yet been administered in pregnancy and the necessary safety studies in pregnant women have not been conducted 25, 30, 31) .
Recent studies showed that Ureaplasma spp. self-replicate, and can form a biofilm 32) . Although the biofilm shows low virulence, these organisms evade the host immune response and increase the resistance to antibiotic treatment. The exact mechanism remains unknown but complicates treatment options with antibiotics in general 9, 32) and may explain the inconsistent therapy effects.
In summary, there is limited evidence regarding the use of macrolides for the therapeutic treatment of Ureaplasma colonization or the prophylactic use for preventing BPD in preterm infants 7) . The time point, drug, and dose of antibiotic treatment needs to be studied in future clinical trials to optimize the outcome. Ideally, the antibiotic treatment should start in utero.
There was no significant difference if both amniotic fluid and gastric fluid were tested positive 22) .
In summary, the best diagnostic tool and approach remains to be identified. With the current development of less invasive surfactant administration that avoids intubation, less tracheal aspirates will be available. Therefore, cultures from other materials, such as nasopharyngeal swabs, ear swabs or gastric fluids, are necessary. However, no data are available supporting the practical use and reliability of these swabs for testing premature infants. This may be a limitation to diagnosis and therefore limit the prevention and treatment of BPD.
UREAPLASMA AND TREATMENT
In analyzing the characteristics and pathophysiologic behavior of Ureaplasma spp., therapeutic and prophylactic treatment of BPD appear to be important. Treatment of these infections may reduce the incidence, severity, morbidity and mortality of BPD.
However, how and when do we treat Ureaplasma spp. when . In vitro and in vivo experimental models also confirmed that macrolides are preferentially concentrated in the lung epithelial lining fluid and alveolar macrophages where they show antimicrobial activity against Ureaplasma spp. Treatment with these antibiotics may therefore enhance Ureaplasma clearance and reduce the risk of developing BPD 19) . However, half of the U. urealyticum strains were shown to be resistant against erythromycin 10) . A Cochrane review in 2003 revealed that treatment of intubated preterm infants at risk for BPD or colonized or infected with Ureaplasma with erythromycin failed to prevent the development of BPD 23) . In vitro studies showed that clarithromycin, josamycin and azithromycin were the most potent macrolides against
Ureaplasma, compared to erythromycin. Higher drug concentration in lung epithelium were observed in these studies 10, [24] [25] [26] . 
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